Eli Lilly stock consolidates as Mounjaro momentum lifts guidance and earnings

Eli Lilly stock reflects strong demand for diabetes and obesity drugs as the US pharma group raises its 2025 guidance after double digit revenue growth and sharply higher earnings.

Eli Lilly & Co. (ISIN US5324571083) stock trades against a backdrop of robust earnings growth, as the US pharmaceutical group lifted guidance for 2025 on the back of surging demand for its diabetes and obesity franchise. According to the companys latest reported full year results for 2024, revenue increased double digits while new launches such as Mounjaro and Zepbound reshaped the sales mix and earnings profile.

Revenue up strongly in 2024

In its 2024 financial year, Eli Lilly reported group revenue of roughly $42 billion, up clearly more than ten percent compared with 2023, driven primarily by incretin based therapies for diabetes and obesity. Within that total, sales of its GLP 1 based diabetes medicine Mounjaro and its obesity brand Zepbound together contributed well over $10 billion in 2024, after only a few billion dollars in the prior year as the products ramped rapidly from launch.

Net income for 2024 rose to well above $10 billion compared with a mid single digit billion figure in 2023, reflecting both the higher topline and operating leverage as fixed costs were spread over a larger revenue base. On an adjusted basis, earnings per share moved from a mid single digit dollar level in 2023 to a low double digit dollar level in 2024, highlighting the profitability impact of the newer drugs. Management attributed much of this earnings expansion to higher volumes rather than price, underlining the structural nature of demand.

Guidance raised for 2025 on obesity demand

For 2025, Eli Lilly raised its revenue and earnings guidance relative to its earlier outlook, citing stronger than previously expected uptake of its obesity treatment. The company now targets 2025 revenue in a mid $40 billion to high $40 billion range, compared with its earlier expectation around the low $40 billion area, implying additional growth potential of several billion dollars. At the midpoint, this would represent a further mid to high single digit percentage increase on top of the strong 2024 base.

The updated 2025 earnings per share guidance likewise moved higher, with Eli Lilly now expecting adjusted EPS in a range implying growth of at least a couple of dollars per share versus 2024. The company signaled that manufacturing investments and capacity expansions for its incretin drugs will remain elevated in 2025, but that margins should still improve modestly as scale effects more than offset higher costs. For investors, the guidance change underscores how central obesity and diabetes therapies have become for the groups growth algorithm.

Mounjaro and Zepbound drive growth

Mounjaro, Eli Lillys once weekly injectable for type 2 diabetes, has rapidly become one of the key growth pillars of the group. In 2024, Mounjaro sales rose by several billion dollars year on year as more patients switched from older therapies and as reimbursement coverage expanded in major markets including the United States. The drug has demonstrated strong efficacy in lowering blood glucose and inducing weight loss, which has also supported demand beyond the core diabetes indication.

Zepbound, approved for chronic weight management, also contributed increasingly to Eli Lillys topline in 2024 and early 2025. Launch revenues climbed from a small base in its first quarters on the market to multiple billions of dollars on an annualized basis, making it one of the fastest growing products in the companys history. The firm has been working to increase production capacity to meet demand, particularly in the United States where obesity prevalence and payer interest in weight loss therapies are high.

Eli Lilly stock and market positioning

Eli Lilly stock is listed on the New York Stock Exchange and forms part of the S&P 500, giving it broad visibility among institutional and index investors. The companys market capitalization has climbed alongside its earnings expansion, reaching a level well above $500 billion by early 2025 compared with a figure closer to the $300 billion area around 2023. That shift reflects both higher earnings and a rerating as investors price in multi year growth from obesity and diabetes franchises.

On a one year view into early 2025, Eli Lilly shares have delivered a strong double digit percentage total return, outperforming the broader US large cap healthcare sector over the same period. The stock has traded near record highs at times, with investors weighing the upside from expanding indications and international rollouts against execution risks such as manufacturing scale up, competitive entries, and potential changes in reimbursement frameworks.

Tirzepatide based therapies at the core

At the product level, the companys tirzepatide based therapies Mounjaro for diabetes and Zepbound for obesity have become central to its medium term strategy. Clinical data have shown significant weight loss and glycemic control compared with several older standard of care options, and Eli Lilly continues to study tirzepatide in additional indications such as sleep apnea and cardiovascular risk reduction. Positive outcomes in these programs could support further revenue growth beyond the current diabetes and obesity markets.

Alongside tirzepatide, Eli Lilly maintains a broad portfolio in oncology, immunology, neuroscience, and other areas, with legacy products providing cash flow to support research and development. The company has guided to research and development expenses in the high single digit to low double digit billions of dollars per year, reflecting a commitment to pipeline renewal even as current blockbusters generate substantial profits.

Eli Lilly stock price and valuation

From a valuation perspective, Eli Lilly stock trades on earnings multiples above the historical average for large cap pharmaceutical companies, a reflection of investor expectations for sustained high growth from obesity and diabetes treatments. The companys price to earnings ratio based on 2024 adjusted EPS stands well above the broader S&P 500 healthcare sector, which means that delivering on the raised 2025 guidance is important for justifying the premium.

For market participants, key watchpoints over the coming quarters include the pace of capacity expansion for incretin therapies, competitive data from rival drugmakers in weight loss and diabetes, and regulatory developments affecting pricing and coverage. The combination of strong current earnings growth, an expanded 2025 outlook, and execution requirements makes Eli Lilly one of the more closely watched names in global pharmaceuticals.

Mounjaro as a flagship product

Mounjaro is positioned as Eli Lillys flagship diabetes medicine, leveraging the dual GIP and GLP 1 mechanism to deliver robust glucose control and weight reduction. Physicians have increasingly prescribed the drug for patients who do not achieve sufficient control on older therapies, which helps explain the multibillion dollar increase in annual Mounjaro revenue between 2023 and 2024. As access expands in additional geographies, the product is expected to deepen its contribution to the companys overall growth.

Eli Lilly stock in a long term context

Looking beyond the one year horizon, Eli Lillys combination of high growth obesity and diabetes drugs, an advancing late stage pipeline, and disciplined capital allocation provides a foundation for continued relevance in global healthcare portfolios. The raised 2025 revenue and earnings guidance, coming on top of double digit revenue growth and higher net income in 2024 compared with 2023, underlines the momentum behind the current strategy. For investors, Eli Lilly stock represents a case where product level innovation directly feeds through into financial results and market valuation.

Key data on Eli Lilly stock

• Company: Eli Lilly & Co.
• ISIN: US5324571083
• Ticker: NYSE: LLY
• Trading venue: NYSE
• Price (as of 17 July 2026, 22:00 ET): value USD
• Market capitalization: above 500 billion USD (as of early 2025)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500